29.07.2009

 
 
London, UK, June 30, 2009: Chiltern, a leading global full service clinical research organisation, has
announced its results for the year ended 31 March 2009.
 
Highlights

• Revenues of £73.7 million, 44% increase over March 2008. Of this growth, 15% is due to acquisitions;
• EBITDA of £9.48 million, 57% increase over March 2008;
• Backlog grew 43% to £137 million at 31 March 2009, up from £93 million at 31 March 2008;
• New business awards of £116 million, 29% increase over March 2008;
• Operating cash flow of £8.6 million;
• Capital expenditure of £1.0 million mainly comprises investment in new systems and IT infrastructure;
• Largest client represented 10% of revenue; top 10 clients represent 48% of revenue. 84% of studies active at 31 March 2009 represent repeat business.

 

Three year results summary 

 

 

 
Commentary 
 
Commenting on the results, Glenn Kerkhof, CEO of Chiltern, said “Chiltern has had a very successful 
year and we are excited that Chiltern is emerging rapidly as a leading global clinical research organisation.  
 
We are growing significantly faster than the sector average. We provide global and high quality services to 
our clients at reasonable prices and in an era of uncertainty we are pleased that this is proving to be a 
very successful formula. 
 
We continue to develop and deepen our experience and expertise in each of our business units and 
expand our geographic network. We look forward to another year of progress despite the difficult market 
conditions.” 
 
Abridged Consolidated Balance Sheet – 31 March 2009 
 

 

 

 

Abridged Consolidated Cash Flow Statement - for the year ended 31 March 2009 

 

 

 

Notes 
 
Chiltern International Group Limited is incorporated in Scotland and subject to the requirements of the 
United Kingdom Companies Act 1985. The above figures do not constitute the statutory financial 
statements of Chiltern International Group Limited as defined under the Companies Act 1985. They have 
been extracted from the consolidated financial statements of Chiltern International Group Limited on 
which the auditors have expressed an unqualified and unmodified opinion. Copies of the statutory financial 
statements may be obtained from the United Kingdom Registrar of Companies. 

 

 
Company profile 
 
About Chiltern: 
Established in 1982, Chiltern is a leading global Clinical Research Organisation with extensive experience 
conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic 
areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries and employs 
1,400 staff across 29 countries. In 2009/10, 64% of revenues are expected to arise in Europe, 32% in 
North America and 4% in the Rest of the World. Chiltern provides services including Early Phase, Global 
Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions.  
Further information is available at www.chiltern.com. 

 

For More Information Contact: 
 
Roland Boyd 
Chief Financial Officer 
Chiltern International Ltd 
171 Bath Road 
Slough 
Berkshire SL1 4AA 
UNITED KINGDOM 
Tel: 44 (0) 1753 512 000 
Fax: 44 (0) 1753 511 116 
Email: roland.boyd@chiltern.com 


 

Back to list